MX2018005894A - Composicion farmaceutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmaceuticamente aceptable del mismo. - Google Patents

Composicion farmaceutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmaceuticamente aceptable del mismo.

Info

Publication number
MX2018005894A
MX2018005894A MX2018005894A MX2018005894A MX2018005894A MX 2018005894 A MX2018005894 A MX 2018005894A MX 2018005894 A MX2018005894 A MX 2018005894A MX 2018005894 A MX2018005894 A MX 2018005894A MX 2018005894 A MX2018005894 A MX 2018005894A
Authority
MX
Mexico
Prior art keywords
azaindolin
derivative
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
Prior art date
Application number
MX2018005894A
Other languages
English (en)
Inventor
Seon Jeong Byeong-
Ae KIM Jung-
Nam Tae-Gyu
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MX2018005894A publication Critical patent/MX2018005894A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se relaciona a un derivado de 7-azaindolin-2-ona o una sal farmacéuticamente aceptable del mismo, y el derivado de 7-azaindolin-2-ona o la sal farmacéuticamente aceptable del mismo se puede utilizar favorablemente como un material medicinal para inhibir el crecimiento de cáncer y metástasis de cáncer.
MX2018005894A 2015-11-12 2016-10-31 Composicion farmaceutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmaceuticamente aceptable del mismo. MX2018005894A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150158695 2015-11-12
PCT/KR2016/012409 WO2017082569A1 (ko) 2015-11-12 2016-10-31 7-아자인돌린-2-온 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 약학 조성물

Publications (1)

Publication Number Publication Date
MX2018005894A true MX2018005894A (es) 2018-08-15

Family

ID=58695675

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005894A MX2018005894A (es) 2015-11-12 2016-10-31 Composicion farmaceutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmaceuticamente aceptable del mismo.

Country Status (18)

Country Link
US (1) US10544140B2 (es)
EP (1) EP3363799A4 (es)
JP (1) JP6661766B2 (es)
KR (1) KR102109869B1 (es)
CN (1) CN108368108B (es)
AU (1) AU2016353573B2 (es)
BR (1) BR112018009482A2 (es)
CA (1) CA3004595A1 (es)
CL (1) CL2018001236A1 (es)
CO (1) CO2018005367A2 (es)
EA (1) EA201891136A1 (es)
IL (1) IL259083A (es)
MA (1) MA42361A1 (es)
MX (1) MX2018005894A (es)
NZ (1) NZ742228A (es)
PH (1) PH12018500946A1 (es)
WO (1) WO2017082569A1 (es)
ZA (1) ZA201803722B (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
JP2002522452A (ja) * 1998-08-04 2002-07-23 スージェン・インコーポレーテッド 蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン
EP1244672B1 (en) * 1999-12-21 2005-07-20 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
CN102066362B (zh) * 2008-05-23 2014-07-30 上海医药工业研究院 二氢吲哚酮衍生物
US9040555B2 (en) * 2012-01-26 2015-05-26 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
BR112015022431A2 (pt) * 2013-03-13 2017-05-09 Boston Biomedical Inc derivados de 3-(aril ou heteroaril) metilenoindolin-2-ona como inibidores de quinases da via de sinalização de células-tronco cancerosas para o tratamento de câncer
CN104876928B (zh) * 2015-05-07 2016-09-14 浙江司太立制药股份有限公司 7-氮杂吲哚啉-2-酮类化合物及其制备方法

Also Published As

Publication number Publication date
KR20170056430A (ko) 2017-05-23
CN108368108A (zh) 2018-08-03
KR102109869B1 (ko) 2020-05-13
EP3363799A4 (en) 2018-12-05
ZA201803722B (en) 2019-03-27
CN108368108B (zh) 2021-09-21
AU2016353573B2 (en) 2019-11-21
WO2017082569A1 (ko) 2017-05-18
CA3004595A1 (en) 2017-05-18
PH12018500946A1 (en) 2018-11-12
AU2016353573A1 (en) 2018-05-24
JP6661766B2 (ja) 2020-03-11
IL259083A (en) 2018-06-28
CL2018001236A1 (es) 2018-08-24
US10544140B2 (en) 2020-01-28
MA42361A1 (fr) 2018-09-28
US20180370964A1 (en) 2018-12-27
JP2018533600A (ja) 2018-11-15
CO2018005367A2 (es) 2018-06-12
BR112018009482A2 (pt) 2018-11-06
EA201891136A1 (ru) 2018-10-31
EP3363799A1 (en) 2018-08-22
NZ742228A (en) 2019-09-27

Similar Documents

Publication Publication Date Title
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
EP3895717A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING WEISSELLA CIBARIA WIKIM28 AS ACTIVE SUBSTANCE
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2016011865A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos.
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
EP3093023A4 (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
NZ710291A (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions
MX2016001422A (es) Composicion farmaceutica de fingolimod.
ZA201907588B (en) Potent hiv inhibiting lipopeptide, derivative thereof, pharmaceutical composition thereof and use thereof
MX2017009289A (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
EP3539978A4 (en) NKX3.2 FRAGMENT AND PHARMACEUTICAL COMPOSITION WITH IT AS THE ACTIVE INGREDIENT
TN2016000490A1 (en) Naphthyridinedione derivatives.
MX2017008983A (es) Composición farmaceútica de sulfonamida.
EA201691741A1 (ru) Фармацевтическая композиция
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
EP3398608A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER OR CANCER METASTASES WITH PSTL1-PRTEIN AS AN ACTIVE SUBSTANCE
EP3404020A4 (en) PYRIDINOL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT
WO2016020408A3 (en) Compounds for preventing ototoxicity
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
PH12018500946A1 (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
HK1251988A1 (zh) 包含作為活性成分的色甘酸或其藥學上可接受的鹽的用於預防和治療肝臟疾病的藥物組合物
IL262490A (en) Lomacaptor complexes and their salts and derivatives, a process for their preparation and pharmaceutical preparations containing them